News & Events

SAN JOSE, Calif.--(BUSINESS WIRE)--April 16, 2002--BD Biosciences and NuGenesis Technologies announced today they have entered into a strategic alliance to provide a productivity solution in an easy-to-use data management and archival system for flow cytometry data.

This new data management solution will use the NuGenesis® Scientific Data Management System (SDMS), which helps pharmaceutical and biotechnology companies meet the requirements of FDA Rule 21 CFR Part 11. This rule applies to the use of electronic records and signatures for companies in regulated industries, including those involved in the discovery of new drug candidates.

Under the terms of this agreement, NuGenesis Technologies will integrate its NuGenesis SDMS technology with BD Biosciences technology for flow cytometry data management and analysis. In addition, BD Biosciences will adopt and sell the NuGenesis SDMS technology to its end users. Additional terms of the agreement were not disclosed.

''We believe this strategic alliance will provide flow cytometrists with a secure data management solution that allows electronic access to data and the ability to share data globally within an organization,'' said Rudy Mareel, Vice President and General Manager, BD Biosciences Immunocytometry Systems. ''In addition, this data management solution could integrate with many other analytical instruments used by the pharmaceutical/biotechnology industry that already take advantage of the NuGenesis SDMS technology, including high-performance liquid chromatographs, gas chromatographs, and mass spectrometers.''

NuGenesis Technologies President and CEO, Michael E. McGuinness, remarked, ''BD Biosciences Immunocytometry Systems differentiates itself on the basis of providing total system solutions, high-quality products, and global distribution; we believe this agreement enables BD Biosciences to provide laboratories with improved productivity and quality advantages. In addition, the adoption of our technology by BD Biosciences further confirms our leadership position and expertise in scientific data management.''

About BD Biosciences

BD Biosciences is a business segment of BD (Becton, Dickinson and Company; NYSE: BDX) and is built on BD's 100-year foundation of quality, reliability, and commitment to customers and business partners around the world. As one of the largest businesses supporting the life sciences worldwide, BD Biosciences provides biotechnology tools leveraging its expertise in molecular biology, cellular biology, immunology, and cell analysis. With four renowned business units--Clontech, Discovery Labware, Immunocytometry Systems, and Pharmingen--BD Biosciences provides integrated, high-value products and services for a variety of applications in the life sciences, including genomics, proteomics, ADME/Tox, oncology, and immune function. Its customers include academic and government institutions focused on basic and clinical research in the life sciences; biotechnology and pharmaceutical companies engaged in drug discovery and development; and hospitals, reference laboratories, and blood banks that perform patient testing and monitoring for quality control. BD Biosciences operates globally, with regional offices in Asia-Pacific, Canada, Europe, Japan, Latin America, and the United States. From genes to proteins to cells, BD Biosciences provides a comprehensive portfolio of reagents, systems, and technical expertise, offering solutions to life scientists and accelerating the pace of biomedical discovery. For the fiscal year ended September 30, 2001, BD Biosciences reported revenues of $592 million. More information can be found at www.bdbiosciences.com.

About BD

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. For the fiscal year ended September 30, 2001, BD reported total revenues of $3.8 billion.

About NuGenesis Technologies

NuGenesis Technologies Corporation, headquartered in Westborough, Massachusetts, is the market leader in scientific data management. The company's products and services provide businesses that rely on electronic data with new opportunities to generate competitive advantage, leverage innovation, and create value. The patented, Web-enabled NuGenesis SDMS technology provides new efficiencies in data management, retrieval, and report development to fast-growing science-based companies--so that skilled employees can focus on analysis, interpretation, and decision-making. More information can be found at www.nugenesis.com.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. BD does not intend to update any forward-looking statements.

--------------------------------------------------------------------------------

Contact:

BD Biosciences

Vera Imper, 408/954-6047
Lisa English, 408/954-2339

or

Nugenesis

Carolyn Lynch, 508/616-9876
clynch@nugenesis.com